Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Second Time's The Charm: Novartis' New Bid Lures Chiron

This article was originally published in The Pink Sheet Daily

Executive Summary

Chiron's vaccines unit will operate as a separate division while its biopharmaceuticals unit will merge with Novartis' pharmaceutical business.
Advertisement

Related Content

Flu Vaccine 2006-2007 Strains To Be Determined By Advisory Cmte. Feb. 17
Flu Vaccine 2006-2007 Strains To Be Determined By Advisory Cmte. Feb. 17
Chiron Minority Shareholder Will Oppose Novartis Takeover
Novartis Considers Joining Swiss Vaccines Firm Berna With Chiron
Novartis Considers Joining Swiss Vaccines Firm Berna With Chiron
Chiron Minority Shareholder Will Oppose Novartis Takeover
GSK To Gain Fluviral Vaccine Through Acquisition Of ID Biomedical
Chiron Seeking To Bump Up Buyout Bid? Directors Reject Novartis’ Offer
Chiron Seeking To Bump Up Buyout Bid? Directors Reject Novartis’ Offer
Novartis Boosts Sandoz Generic Business With Acquisition Of Eon, Hexal

Topics

Advertisement
UsernamePublicRestriction

Register

PS061201

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel